08Dec 2023
Metastasis-Free Survival As A Surrogate Endpoint For Overall Survival In Localized Prostate Cancer

Metastasis-Free Survival As A Surrogate Endpoint For Overall Survival In Localized Prostate Cancer

The ICECaP-2 study, building on prior research, validated metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (PCa). The study included 15,164 patients from 14 trials, with 70% treated after 2004 when docetaxel became more available for metastatic castrate-resistant prostate cancer. The surrogacy condition showed strong correlation at both patient and trial levels, supporting the continued use of MFS as a primary outcome in ongoing adjuvant trials for localized PCa.

  • #oncology

Like

Save

Share